期刊文献+

严重开放性胸腹部外伤抢救成功一例 被引量:2

下载PDF
导出
摘要 患者:男性,59岁.因被高速运转飞轮碎片击中左胸背部疼痛流血1 h余入院,伤后立即送入我院急诊,因病情危急,来不及做任何检查,伤口包扎后直接送入手术室.入室查体,患者神志淡漠,血压50/30 mm Hg,面色苍白,急性失血貌.右侧卧位后探查,见左腰背处,从第11肋骨下缘始,达左肾区,有一斜行长约15 cm裂口,可见肋骨骨折及断端,并可见部分脾脏已碎裂,伤口涌出大量鲜血及血凝块.立即建立两条静脉通道,同时,麻醉师行锁骨下静脉穿刺,加快补液速度,做术前准备,立即在全身麻醉下行剖腹探查术.取左上腹直肌探查切口,见出血量约3 000 ml,脾脏粉碎状破裂,脾蒂已被切断,立即钳夹脾蒂止血,快速切除脾脏.进一步探查见左肾上1/3已被切断,残余大部分左肾断面可见出血,术中请泌尿外科会诊,因不能确定右肾功能是否正常,决定行左肾上极切除,残余左肾创面止血并缝合.
出处 《腹部外科》 2013年第6期379-379,共1页 Journal of Abdominal Surgery
  • 相关文献

参考文献14

  • 1Debiec-Rychter M,Sciot R,Le Cesne A,et al.KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Eur J Cancer,2006,1093-1103.
  • 2Heinrich MC,Owzar K,Corless CL,et al.Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of Imatinib Mesylate for treatment of advanced gastrointestinal stromal tumor:CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group.J Clin Oncol,2008,26:5360-5367.
  • 3Corless CL,Ballman KU,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):results of the intergroup phase III trial ACOSOG Z9001.J Clin Oncol,2010,28:a10006.
  • 4Joensuu H,Eriksson M,Sundby Hall K,et al.One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor:a randomized trial.JAMA,2012,307:1265-1272.
  • 5Rubin BP,Heinrich MC,Corless CL.Gastrointestinal stromal tumor.Lancet,2007,369:1731-1741.
  • 6Gold JS,van der Zwan SM,Gonen M,et al.Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.Ann Surg Oncol,2007,14:134-142.
  • 7Blanke CD,Demetri GD,von Mehren M,et al.Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol,2008,26:620-625.
  • 8Blanke CD,Rankin C,Demetri GD,et al.Phase III randomized,intergroup trial assessing Imatinib Mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase:S0033.J Clin Oncol,2008,26:626-632.
  • 9Le Cesne A,Van Glabbeke M,Verweij J,et al.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate:the intergroup EORTC-ISG-AGITG phase III trial.J Clin Oncol,2009,27:3969-3974.
  • 10Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib:a randomised controlled trial.Lancet,2006,368:1329-1338.

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部